Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.
Also called NCT05767346
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 175 participants
- Sponsor
- Registry
-
NCT05767346
-
- Other papers using this trial's data
- Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
- Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM
- Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy
- Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, China, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05767346. Randomized; triple masking; primary purpose treatment. Start 2023-06-20 (actual); primary completion 2025-02-28 (actual). Results posted on 2026-06-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- Acronym
- MAPLE-HCM
- Condition
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug)
- Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- Intervention (Drug)
- Placebo to match aficamten
- Intervention (Drug)
- Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- Intervention (Drug)
- Placebo to match metoprolol succinate
- Lead sponsor
- Cytokinetics
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct05767346- Content hash
8ae7b46dc80b651c628ee44da6ed1e01256ee5805f17edb13c746d521308256f